Clinical trials: PDAC
Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
This is a prospective, single-center, randomized, open-label, two-arm Phase II clinical trial design to evaluate the feasibility, safety and preliminary efficacy of combining fecal Fecal Microbiota Transplantation （FMT） Combined…
- Trial name
- NCT07845565
- Testing
- FMT+Chemotherapy+Immunotherapy, Chemotherapy+Immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment
The purpose of this study is to evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) affects survival in patients with inoperable pancreatic carcinoma.
- Trial name
- PERFECT (NCT07850336)
- Testing
- Endoscopic ultrasound-guided radiofrequency ablation
- Volunteers
- 56 people
- Sponsor
- Bojan Kovacevic
Colorectal Cancer, CRC
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
- Conditions
- Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06445062
- Testing
- RMC-6236, mFOLFOX6 regimen, bevacizumab
- Where
- 32 sites in United States
- Volunteers
- 1,130 people
- Sponsor
- Revolution Medicines, Inc.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07435038
- Testing
- BPI-572270
- Where
- 7 sites in Australia, China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment or…
- Trial name
- NCT07450859
- Testing
- nuzefatide pevedotin (BT5528)
- Where
- 8 sites in United States, South Korea
- Volunteers
- 39 people
- Sponsor
- BicycleTx Limited
Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
This study intends to explore conversion therapy for locally advanced pancreatic cancer (LAPC). The intervention starts with modified stereotactic body radiation therapy (3-day regimen), followed by systemic therapy within 1-2…
- Trial name
- NCT07827053
- Testing
- Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT
- Volunteers
- 36 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Ductal Adenocarcinoma (PDAC)
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
The purpose of this research is to observe the effects of using a new combination of drugs to inhibit tumor growth.
- Trial name
- FALCON (NCT07829185)
- Testing
- modified FOLFIRINOX, Pentamidine 300 MG Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Oklahoma
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07349537
- Testing
- RMC-5127, daraxonrasib, cetuximab
- Where
- 9 sites in United States
- Volunteers
- 574 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma
The goal of this study is to find out if taking two oral study drugs (avutometinib and defactinib) are safe for patients with pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer
- Trial name
- Panc 004 (NCT07824960)
- Testing
- Avutometinib (VS-6766) + Defactinib (VS-6063)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Virginia
Pancreatic Ductal Adenocarcinoma (PDAC), Hand Grip Strength
Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: Is it feasible to measure hand grip strength as part of a clinic…
- Trial name
- PanFit (NCT07255001)
- Testing
- Hand grip strength assessments using a dynamometer
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Colorectal Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC
The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients.
- Trial name
- COLOPan (NCT07500259)
- Testing
- Personalized Functional Profiling
- Where
- Luxembourg
- Volunteers
- 188 people
- Sponsor
- Luxembourg Institute of Health
Colorectal Cancer, Epithelial Ovarian Cancer
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of [68Ga]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC)…
- Conditions
- Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07702292
- Testing
- [68Ga]BED003
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 71 people
- Sponsor
- Blue Earth Diagnostics
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer.
- Conditions
- Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia
- Trial name
- PEGASUS (NCT05132244)
- Testing
- Glucose Measurements via Blood Draw
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Advanced Solid Tumor, PDAC
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for…
- Conditions
- Advanced Solid Tumor, PDAC, HNSCC
- Trial name
- NCT06597721
- Testing
- ADCE-T02
- Where
- 14 sites in United States, Australia
- Volunteers
- 210 people
- Sponsor
- Adcendo ApS
Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC)
EUS-Based Artificial Intelligence to Predict Outcomes in Pancreatic Cancer
The EUS-AI-R study is an observational, single-center, two-phase (retrospective-prospective) study designed to develop and validate artificial intelligence (AI) models for predicting chemotherapy response and oncological outcomes…
- Conditions
- Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Artificial Intelligence (AI), Endoscopic Ultrasound (EUS)
- Trial name
- EUS-AI-R (NCT07803770)
- Testing
- Endoscopic ultrasound (EUS), with or without tissue acquisition (EUS-FNA/FNB), performed according to standard clinical practice. No study-specific intervention is introduced.
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- IRCCS San Raffaele
Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer…
- Trial name
- NCT07803783
- Testing
- Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil
- Where
- China
- Volunteers
- 320 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage I
Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma
The goal of this observational registry is to examine the changes made to pancreatic cancer surveillance management following the real-world clinical use of PancreaSure testing among individuals at increased risk for pancreatic…
- Conditions
- PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis
- Trial name
- ASSURE (NCT07805681)
- Volunteers
- 400 people
- Sponsor
- Immunovia, Inc.
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT07573215
- Testing
- daraxonrasib
- Where
- 257 sites in United States, Puerto Rico
- Sponsor
- Revolution Medicines, Inc.